LPCN - Lipocine Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Salt Lake City,
United States
Type: Equity
LPCN price evolution
LPCN
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.55 | $3.08 | $4.77 | $4.07 |
| Short term investments | $17 | $21.55 | $17.26 | $19.78 |
| Net receivables | $0.06 | $0.1 | $0.05 | $0.04 |
| Inventory | ||||
| Total current assets | $22.91 | $25.32 | $22.86 | $24.61 |
| Long term investments | ||||
| Property, plant & equipment | $0.1 | $0.11 | $0.12 | $0.11 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.12 | $0.13 | $0.14 | $0.14 |
| Total investments | $17 | $21.55 | $17.26 | $19.78 |
| Total assets | $23.03 | $25.45 | $23 | $24.75 |
| Current liabilities | ||||
| Accounts payable | $0.45 | $0.67 | $1.4 | $1.1 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1.82 | $1.49 | $2.63 | $2.24 |
| Long term debt | ||||
| Total noncurrent liabilities | $0.03 | |||
| Total debt | ||||
| Total liabilities | $1.82 | $1.49 | $2.63 | $2.27 |
| Shareholders' equity | ||||
| Retained earnings | -$199.33 | -$196.26 | -$199.78 | -$197.49 |
| Other shareholder equity | -$0.01 | -$0.01 | $0.01 | -$0.01 |
| Total shareholder equity | $21.21 | $23.96 | $20.37 | $22.48 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.77 | $3.15 | $2.95 | $24.22 |
| Short term investments | $17.26 | $29.38 | $41.67 | $0.45 |
| Net receivables | $0.05 | $0.08 | $0.25 | $0 |
| Inventory | ||||
| Total current assets | $22.86 | $34.14 | $46.38 | $25.33 |
| Long term investments | $2.02 | |||
| Property, plant & equipment | $0.12 | $0.13 | $0.01 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.14 | $3.41 | $6.1 | $0.02 |
| Total investments | $17.26 | $29.38 | $43.69 | $0.45 |
| Total assets | $23 | $37.54 | $52.48 | $25.35 |
| Current liabilities | ||||
| Accounts payable | $1.4 | $0.6 | $1.29 | $1.6 |
| Deferred revenue | ||||
| Short long term debt | $2.31 | $3.33 | ||
| Total current liabilities | $2.63 | $1.68 | $5.62 | $6.58 |
| Long term debt | $2.26 | |||
| Total noncurrent liabilities | $0.23 | $1.3 | $3.43 | |
| Total debt | $2.31 | $5.59 | ||
| Total liabilities | $2.63 | $1.91 | $6.91 | $10.01 |
| Shareholders' equity | ||||
| Retained earnings | -$199.78 | -$183.43 | -$172.67 | -$172.03 |
| Other shareholder equity | $0.01 | -$0.02 | -$0.02 | -$0.04 |
| Total shareholder equity | $20.37 | $35.63 | $45.57 | $15.34 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.09 | $7.62 | $0.22 | |
| Cost of revenue | ||||
| Gross Profit | $0.09 | $7.62 | $0.22 | |
| Operating activities | ||||
| Research & development | $1.87 | $2.82 | $1.67 | |
| Selling, general & administrative | $1.51 | $1.58 | $1.13 | |
| Total operating expenses | $3.38 | $4.39 | $2.81 | |
| Operating income | -$3.29 | $3.22 | -$2.59 | |
| Income from continuing operations | ||||
| EBIT | -$3.07 | $3.51 | -$2.28 | |
| Income tax expense | $0 | $0 | $0 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$3.07 | $3.51 | -$2.28 | |
| Income (for common shares) | -$3.07 | $3.51 | -$2.28 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | -$2.85 | $0.5 | $16.14 | |
| Cost of revenue | ||||
| Gross Profit | -$2.85 | $0.5 | $16.14 | |
| Operating activities | ||||
| Research & development | $10.18 | $8.56 | $7.67 | $9.75 |
| Selling, general & administrative | $4.9 | $4.06 | $5.33 | $8.25 |
| Total operating expenses | $15.08 | $12.62 | $13 | $18 |
| Operating income | -$17.93 | -$12.12 | $3.15 | -$18 |
| Income from continuing operations | ||||
| EBIT | -$16.35 | -$10.73 | -$0.43 | -$20.58 |
| Income tax expense | $0 | $0 | $0 | $0 |
| Interest expense | $0.03 | $0.2 | $0.39 | |
| Net income | ||||
| Net income | -$16.35 | -$10.76 | -$0.63 | -$20.96 |
| Income (for common shares) | -$16.35 | -$10.76 | -$0.63 | -$20.96 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$3.07 | $3.51 | -$2.28 | -$6.65 |
| Operating activities | ||||
| Depreciation | $0.01 | $0.01 | $0.01 | $0.01 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.1 | $0.1 | $0.15 | $0.16 |
| Total cash flows from operations | -$2.5 | $2.41 | -$2.02 | -$2.61 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | |||
| Investments | $4.75 | -$4.09 | $2.74 | $1.24 |
| Total cash flows from investing | $4.75 | -$4.09 | $2.73 | $1.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.21 | -$0.01 | $0.41 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.22 | -$0.01 | -$0.01 | $0.42 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $2.47 | -$1.69 | $0.7 | -$0.94 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$16.35 | -$10.76 | -$0.63 | -$20.96 |
| Operating activities | ||||
| Depreciation | $0.03 | $0.01 | $0 | $0 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.65 | $0.64 | $0.6 | $1.37 |
| Total cash flows from operations | -$11.87 | -$11.97 | -$4.41 | -$15.3 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.13 | -$0.01 | |
| Investments | $13.1 | $14.43 | -$43.77 | $3.89 |
| Total cash flows from investing | $13.08 | $14.29 | -$43.78 | $3.89 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.4 | $0.19 | $30.26 | $22.33 |
| Net borrowings | -$2.32 | -$3.33 | -$1.43 | |
| Total cash flows from financing | $0.4 | -$2.13 | $26.92 | $20.9 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $1.62 | $0.2 | -$21.27 | $9.49 |
News
Fundamentals
| Market cap | $26.74M |
|---|---|
| Enterprise value | $21.19M |
| Shares outstanding | 5.35M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 1.26 |
| Book/Share | 3.97 |
| Cash/Share | 1.04 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.13 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 12.56 |
| Quick ratio | 12.56 |